Summary
Background Endogenous retroelements (EREs), including human endogenous retroviruses (HERVs) and long interspersed nuclear elements (LINEs), comprise almost half of the human genome. HIV-1 infects a target cell already possessing ancient retroviral genetic material, and exogenous HIV-1 infection modulates the expression of cell associated EREs. Following initial HIV-1 infection, there is a rapid destruction of CD4+ cells in the gut associated lymphoid tissue (GALT). Our previous studies of the interferome in the gut suggest potential mechanisms regarding how IFNb may drive HIV-1 gut pathogenesis. As ERE activity is suggested to partake in type 1 immune responses and is incredibly sensitive to viral infections, we sought to elucidate underlying interactions between ERE expression and GALT dynamics in PLWH.
Methods ERE expression profiles from bulk RNA sequencing of colon biopsies and PBMC were compared between a cohort of PLWH prior to or within 7 days of initiating antiretroviral therapy (ART) (n=19) and uninfected controls (n=13). Individual EREs were then compared with the profiling of uninfected gut CD4+ T cells activated with type 1 interferons (IFN-Is) (n=3) to elucidate potential mechanisms for their induction in PLWH.
Findings 59 EREs were differentially expressed in the colon of PLWH when compared to uninfected controls (Wald’s Test with Benjamin-Hochberg correction: padj < 0.05 and FC ≤ −1 or ≥ 1). Of these 59, 12 EREs were downregulated in PLWH and 47 were upregulated. Colonic expression of the ERE loci LTR19_12p13.31 and L1FLnI_1q23.1s showed significant correlations with CD8+ T Cells and dendritic cell subset frequencies in the GI tract (Spearman’s Correlation: p value < 0.05). Furthermore L1FLnI_1q23.1s showed a significant upregulation in the blood of PLWH when compared to uninfected controls (T test: p <0.05) suggesting a common mechanism of differential ERE expression in PBMC and GALT.
Interpretation ERE activity has been largely understudied in genomic characterizations of human pathologies. We show that the activity of certain EREs in the GI tract of PLWH is deregulated, supporting our hypotheses that their underlying activity could function as (bio)markers and potential mediators of pathogenesis in HIV-1 reservoirs.
Funding NCI CA260691 (DFN) and NIAID UM1AI164559 (DFN).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by NCI CA260691 and NIAID UM1AI164559
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Analyses performed in this study were performed on deidentified and publicly available or previously archived data. The original clinical study was approved by the Colorado Multiple Institutional Review Board and all study participants voluntarily gave written, informed consent ERE expression analyses were conducted using FASTQ files from previously generated RNAseq data collected from colonic tissue and PBMC fractions collected from 19 PLWH and 13 age and sex matched controls, and associations with features of HIV 1 pathogenesis were determined using archived datasets of colon and systemic immunological and virological parameters. The relevant studies pertaining to the original data are as follows: Guo, K. et al. Qualitative Differences Between the IFNα subtypes and IFNb Influence Chronic Mucosal HIV 1 Pathogenesis. PLoS Pathog. 16, e1008986 (2020). Dillon, S. M. et al. A Compartmentalized Type I Interferon Response in the Gut During Chronic HIV 1 Infection is Associated with Immunopathogenesis. AIDS Lond. Engl. 32, 1599 1611 (2018). Dillon, S. M. et al. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol. 7, 983 994 (2014). Dillon, S. M. et al. Gut dendritic cell activation links an altered colonic microbiome to mucosal and systemic T cell activation in untreated HIV 1 infection. Mucosal Immunol. 9, 24 37 (2016).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
